Title

Developing Drugs for Negative Symptoms of Schizophrenia

Translated Titles

發展治療思覺失調症負性症狀的藥物

Authors

劉智民(Chih-Min Liu)

Key Words

schizophrenia ; negative symptoms ; medication ; clinical trials ; 思覺失調症 ; 負性症狀 ; 藥物 ; 臨床試驗

PublicationName

臺灣精神醫學

Volume or Term/Year and Month of Publication

31卷2期(2017 / 06 / 01)

Page #

115 - 127+ii

Content Language

英文

Chinese Abstract

Negative symptoms in schizophrenia represent a clinically important target for drug development due to their profound effect on an individual’s ability to function normally. The lack of effective medications for this domain of psychopathology is a major unmet medical need in schizophrenia. Earlier clinical trials for negative symptoms have been criticized mixing primary and secondary negative symptoms as treatment target and lack of standard protocols for clinical trial design. In the first part, The author is reviewing the methodological issues on defining and measuring negative symptoms and on developing the consensus for clinical trial design for negative symptoms. Deficit symptoms and persistent negative symptoms, instead of broadly defined negative symptoms, have been advocated as the treatment target of clinical trial. There were five commonly used interviewbased negative symptom scales with satisfactory psychometric profiles. The consensus has been achieved for the design of clinical trials for negative symptoms. In the second part, the treatment efficacy of different class of drugs on negative symptoms is reviewed. Some second-generation antipsychotics, antidepressants, psychostimulants, glutamate pathway molecules, serotonin receptor antagonists, and anti-inflammatory agents have modest effects on improving negative symptoms than placebo. Although some statistically significant effects on negative symptoms are evident, none has reached the threshold for clinically significant. Several new molecules with potentials in treating negative symptoms are still in development.

English Abstract

思覺失調症的負性症狀,因為影響病人的功能甚鉅,是臨床上發展藥物治療的重要標的。這個症狀群仍缺乏有效的治療,是目前重大的未能滿足的治療需求。早期的負性症狀的臨床試驗,因為同時包括首發的及次發的負性症狀為治療標的,以及缺乏標準的試驗流程,而備受批評。本篇綜說第一部份將會回顧負性症狀臨床試驗相關的方法學,包括負性症狀的定義及量測,以及臨床試驗設計原則的共識。缺損症狀及持續性負性症狀,而非廣義的負性症狀,更適合做為臨床試驗的治療標的。目前有五種常用的由訪談者評估的負性症狀量表做為評估工具,皆有不錯的心理計量品質。目前專家已達成臨床試驗設計原則的共識。第二部份將回顧不同種類藥物對負性症狀的治療效果,結果顯示某些第二代抗精神病藥物,抗憂鬱劑,精神刺激劑,麩胺酸路徑相關分子,血清素受體拮抗劑,已及某些抗發炎藥物,比起安慰劑,對負性症狀有顯著但輕微的治療效果。上述藥物雖然在負性症狀的進步上達到顯著,在臨床上卻尚未達到顯著進步的程度。目前仍有一些有潛力的新分子仍在發展中。

Topic Category 醫藥衛生 > 社會醫學
Reference
  1. Akhondzadeh, S,Malek-Hosseini, M,Ghoreishi, A,Raznahan, M,Rezazadeh, SA(2008).Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebocontrolled study.Prog Neuropsychopharmacol Biol Psychiatry,32,1879-1883.
  2. Alphs, LD,Summerfelt, A,Lann, H,Muller, RJ(1989).The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia.Psychopharmacol Bull,25,159-163.
  3. Andrade, C,Kisely, S,Monteiro, I,Rao, S(2015).Antipsychotic augmentation with modafinil or ar- modafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials.J Psychiatr Res,60,14-21.
  4. Andreasen, NC(1989).The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theo- retical foundations.Br J Psychiatry,Suppl,49-58.
  5. Barnes, TR,Leeson, VC,Paton, C(2016).Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo- controlled, randomised clinical trial.Health Technol Assess,20,1-46.
  6. Barnes, TR,Paton, C(2011).Do antidepressants improve negative symptoms in schizophrenia?.BMJ,342,d3371.
  7. Blanchard, JJ,Cohen, AS(2006).The structure of negative symptoms within schizophrenia: implications for as- sessment.Schizophr Bull,32,238-245.
  8. Bottlender, R,Wegner, U,Wittmann, J,Strauss, A,Moller, HJ(1999).Deficit syndromes in schizophrenic pa- tients 15 years after their first hospitalisation: pre- liminary results of a follow-up study.Eur Arch Psychiatry Clin Neurosci,249(Suppl 4),27-36.
  9. Buchanan, RW(2007).Persistent negative symptoms in schizophrenia: an overview.Schizophr Bull,33,1013-1022.
  10. Bugarski-Kirola, D,Blaettler, T,Arango, C(2016).Bitopertin in negative symptoms of schizophrenia: results from the Phase III FlashLyte and DayLyte Studies.Biol Psychiatry
  11. Carpenter, WT, Jr.,Buchanan, RW,Kirkpatrick, B,Tamminga, C,Wood, F(1993).Strong inference, theory test- ing, and the neuroanatomy of schizophrenia.Arch Gen Psychiatry,50,825-831.
  12. Carpenter, WT, Jr.,Heinrichs, DW,Wagman, AM(1988).Deficit and nondeficit forms of schizophrenia: the concept.Am J Psychiatry,145,578-583.
  13. Carpenter, WT., Jr.(2004).Clinical constructs and therapeu- tic discovery.Schizophr Res,72,69-73.
  14. Daniel, DG(2013).Issues in selection of instruments to mea- sure negative symptoms.Schizophr Res,150,343-345.
  15. Davis, MC,Horan, WP,Marder, SR(2014).Psychopharmacology of the negative symptoms: cur- rent status and prospects for progress.Eur Neuropsychopharmacol,24,788-799.
  16. Duinkerke, SJ,Botter, PA,Jansen, AA(1993).Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-con- trolled double-blind trial.Br J Psychiatry,163,451-455.
  17. Dunayevich, E,Buchanan, RW,Chen, CY(2017).Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.Schizophr Res,182,90-97.
  18. Erhart, SM,Marder, SR,Carpenter, WT(2006).Treatment of schizophrenia negative symptoms: future prospects.Schizophr Bull,32,234-237.
  19. Foussias, G,Siddiqui, I,Fervaha, G,Agid, O,Remington, G(2015).Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.J Psychopharmacol,29,116-126.
  20. Fusar-Poli, P,Papanastasiou, E,Stahl, D(2015).Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials.Schizophr Bull,41,892-899.
  21. Gard, DE,Kring, AM,Gard, MG,Horan, WP,Green, MF(2007).Anhedonia in schizophrenia: distinctions be- tween anticipatory and consummatory pleasure.Schizophr Res,93,253-260.
  22. Goldberg, SC(1985).Negative and deficit symptoms in schizophrenia do respond to neuroleptics.Schizophr Bull,11,453-456.
  23. Horan, WP,Kring, AM,Gur, RE,Reise, SP,Blanchard, JJ(2011).Development and psychometric validation of the Interview for Negative Clinical Symptoms (CAINS).Schizophr Res,132,140-145.
  24. Iranpour, N,Zandifar, A,Farokhnia, M(2016).The ef- fects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.Hum Psychopharmacol,31,103-112.
  25. Kardashev, A,Ratner, Y,Ritsner, MS(2015).Add-on preg- nenolone with L-theanine to antipsychotic therapy relieves negative and anxiety symptoms of schizo- phrenia: an 8-week, randomized, double-blind, pla- cebo-controlled trial.Clin Schizophr Relat Psychoses
  26. Kay, SR,Fiszbein, A,Opler, LA(1987).The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr Bull,13,261-276.
  27. Kelley, ME,van Kammen, DP,Allen, DN(1999).Empirical validation of primary negative symptoms: indepen- dence from effects of medication and psychosis.Am J Psychiatry,156,406-411.
  28. Kirkpatrick, B,Fenton, WS,Carpenter, WT., Jr,Marder, SR(2006).The NIMH-MATRICS consensus statement on negative symptoms.Schizophr Bull,32,214-219.
  29. Kirkpatrick, B,Strauss, GP,Nguyen, L(2011).The brief negative symptom scale: psychometric properties.Schizophr Bull,37,300-305.
  30. Kishi, T,Iwata, N(2013).NMDA receptor antagonists inter- ventions in schizophrenia: Meta-analysis of random- ized, placebo-controlled trials.J Psychiatr Res,47,1143-1149.
  31. Kishi, T,Mukai, T,Matsuda, Y,Iwata, N(2014).Selective se- rotonin 3 receptor antagonist treatment for schizo- phrenia: meta-analysis and systematic review.Neuromolecular Med,16,61-69.
  32. Laughren, T,Levin, R(2011).Food and Drug Administration commentary on methodological issues in negative symptom trials.Schizophr Bull,37,255-256.
  33. Leucht, S,Pitschel-Walz, G,Engel, RR,Kissling, W(2002).Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.Am J Psychiatry,159,180-190.
  34. Levine, SZ,Leucht, S(2012).Delayed- and early-onset hy- potheses of antipsychotic drug action in the negative symptoms of schizophrenia.Eur Neuropsychopharmаcol,22,812-817.
  35. Lindenmayer, JP,Nasrallah, H,Pucci, M,James, S,Citrome, L(2013).A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities.Schizophr Res,147,241-252.
  36. Liu, F,Guo, X,Wu, R(2014).Minocycline supplemen- tation for treatment of negative symptoms in early- phase schizophrenia: a double blind, randomized, controlled trial.Schizophr Res,153,169-176.
  37. Marder, SR,Alphs, L,Anghelescu, IG(2013).Issues and perspectives in designing clinical trials for nega- tive symptoms in schizophrenia.Schizophr Res,150,328-333.
  38. Marder, SR,Kirkpatrick, B(2014).Defining and measuring negative symptoms of schizophrenia in clinical trials.Eur Neuropsychopharmacol,24,737-743.
  39. Marder, SR,Meibach, RC(1994).Risperidone in the treat- ment of schizophrenia.Am J Psychiatry,151,825-835.
  40. Marx, CE,Keefe, RS,Buchanan, RW(2009).Proof-of- concept trial with the neurosteroid pregnenolone tar- geting cognitive and negative symptoms in schizo- phrenia.Neuropsychopharmacology,34,1885-1903.
  41. Nemeth, G,Laszlovszky, I,Czobor, P(2017).Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in pa- tients with schizophrenia: a randomised, double- blind, controlled trial.Lancet,389,1103-1113.
  42. Nikbakhat, MR,Arabzadeh, S,Zeinoddini, A(2016).Duloxetine add-on to risperidone for treatment of Negative Symptoms in patients with stable schizo- phrenia: randomized double-blind placebo-con- trolled study.Pharmacopsychiatry,49,162-169.
  43. Ohgi, Y,Futamura, T,Hashimoto, K(2015).Glutamate Signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders.Curr Mol Med,15,206-221.
  44. Oya, K,Kishi, T,Iwata, N(2014).Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Hum Psychopharmacol,29,483-491.
  45. Plane, JM,Shen, Y,Pleasure, DE,Deng, W(2010).Prospects for minocycline neuroprotection.Arch Neurol,67,1442-1448.
  46. Ritsner, MS,Bawakny, H,Kreinin, A(2014).Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.Psychiatry Clin Neurosci,68,432-440.
  47. Rummel, C,Kissling, W,Leucht, S(2006).Antidepressants for the negative symptoms of schizophrenia.Cochrane Database Syst Rev,CD005581.
  48. Schmidt, CJ,Sorensen, SM,Kehne, JH,Carr, AA,Palfreyman, MG(1995).Palfreyman MG: The role of 5-HT2A receptors in antipsychotic activity.Life Sci,56,2209-2222.
  49. Sepehry, AA,Potvin, S,Elie, R,Stip, E(2007).Selective sero- tonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta- analysis.J Clin Psychiatry,68,604-610.
  50. Singh, SP,Singh, V(2011).Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.CNS Drugs,25,859-885.
  51. Singh, SP,Singh, V,Kar, N,Chan, K(2010).Efficacy of anti- depressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.Br J Psychiatry,197,174-179.
  52. Stauffer, VL,Millen, BA,Andersen, S(2013).Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with promi- nent negative symptoms of schizophrenia compared to placebo.Schizophr Res,150,434-441.
  53. Strauss, GP,Frank, MJ,Waltz, JA(2011).Deficits in positive reinforcement learning and uncertainty-driv- en exploration are associated with distinct aspects of negative symptoms in schizophrenia.Biol Psychiatry,69,424-431.
  54. Strauss, GP,Horan, WP,Kirkpatrick, B(2013).Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.J Psychiatr Res,47,783-790.
  55. Tsai, GE,Lin, PY(2010).Strategies to enhance N-methyl-D- aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.Curr Pharm Des,16,522-537.
  56. Umbricht, D,Alberati, D,Martin-Facklam, M(2014).Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.JAMA Psychiatry,71,637-646.
  57. Usall, J,Huerta-Ramos, E,Labad, J(2016).Raloxifene as an adjunctive treatment for postmenopausal wom- en with schizophrenia: a 24-week double-blind, ran- domized, parallel, placebo-controlled trial.Schizophr Bull,42,309-317.
  58. Ventura, J,Hellemann, GS,Thames, AD,Koellner, V,Nuechterlein, KH(2009).Symptoms as mediators of the re- lationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.Schizophr Res,113,189-199.
  59. Walling, D,Marder, SR,Kane, J(2016).Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.Schizophr Bull,42,335-343.
Times Cited
  1. 張鳳麟,高霈馨(2018).The Need of More Interdisciplinary Collaboration in Understanding Negative Symptoms.臺灣精神醫學,32(4),331-332.